Loading…
Biotech Next Gen 2021 has ended
avatar for Timothy A. Yap, M.B.B.S., Ph.D., F.R.C.P.

Timothy A. Yap, M.B.B.S., Ph.D., F.R.C.P.

The University of Texas MD Anderson Cancer Center
Associate Professor of Investigational Cancer Therapeutics; Medical Director of the Institute for Applied Cancer Science
Dr. Timothy A. Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr. Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes.
 
Prior to his current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK. 
 
Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical and translational studies using novel predictive and pharmacodynamic biomarkers. His main interests include the targeting of the DNA damage response (DDR) with novel therapeutics, such as PARP, ATR, WEE1, RAD51, PK-MYT1 and DNA-PK inhibitors, as well as the development of novel immunotherapeutics.

My Speakers Sessions

Tuesday, June 22
 

1:00pm EDT